← back to search

Alwin Krämer

German Cancer Research Center · DE
Area of research
Hematology · Cell Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Microtubule and mitosis dynamics, Cancer Diagnosis and Treatment, and Chronic Myeloid Leukemia Treatments.
h-index
54
citations
12,688
works
272
NIH funding
primary concept
Biology
email

Recent publications

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial
Journal of Clinical Oncology 2025cited by 10position: middledoi
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment
Nature Reviews Clinical Oncology 2025cited by 5position: lastdoi
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Blood 2025cited by 3position: middledoi
Letter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary
ESMO Open 2025cited by 1position: firstdoi
Etiology of TP53 mutated complex karyotype acute myeloid leukemia
Leukemia 2025cited by 1position: middledoi
Tumour mutational burden: clinical utility, challenges and emerging improvements
Nature Reviews Clinical Oncology 2024cited by 114position: middledoi
Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype
Nature Genetics 2024cited by 29position: middledoi
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary
Clinical Chemistry 2024cited by 7position: lastdoi
STIL overexpression shortens lifespan and reduces tumor formation in mice
PLoS Genetics 2024cited by 2position: lastdoi
Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in <i>RUNX1</i>, <i>GATA2</i>, and <i>DDX41</i>
Blood Advances 2023cited by 37position: middledoi
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Nature Communications 2023cited by 31position: lastdoi
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
European Journal of Cancer 2023cited by 8position: lastdoi
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
Annals of Hematology 2023cited by 7position: middledoi
Cancer of unknown primary (CUP) – lokal begrenzt, oligometastatisch und im Kopf-Hals-Bereich
Die Radiologie 2023cited by 5position: lastdoi
CUP-Syndrom – die neue ESMO-Leitlinie
Die Radiologie 2023cited by 4position: lastdoi
Protocol for high-throughput electron tomography exemplified on centrioles in primary human plasma cells
STAR Protocols 2023cited by 3position: lastdoi
Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
HemaSphere 2023cited by 3position: middledoi
High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
Leukemia 2023cited by 2position: lastdoi
Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
Clinical Lung Cancer 2023cited by 2position: lastdoi
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and &lt;i&gt;KIT&lt;/i&gt; and/or &lt;i&gt;FLT3-&lt;/i&gt;ITD mutations: results of the SAL MIDOKIT trial
Haematologica 2023cited by 1position: middledoi
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Journal of Hematology & Oncology 2022cited by 55position: middledoi
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
Journal of Cancer Research and Clinical Oncology 2022cited by 32position: middledoi
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
Genes Chromosomes and Cancer 2022cited by 12position: lastdoi
Cancer-of-Unknown-Primary-Origin: A SEER–Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice
Cancers 2022cited by 8position: lastdoi
Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in <i>RUNX1</i>, <i>GATA2</i> and <i>DDX41</i>
Blood 2022cited by 6position: middledoi
A high-throughput electron tomography workflow reveals over-elongated centrioles in relapsed/refractory multiple myeloma
Cell Reports Methods 2022cited by 5position: lastdoi
Human SLFN5 and its Xenopus Laevis ortholog regulate entry into mitosis and oocyte meiotic resumption
Cell Death Discovery 2022cited by 2position: lastdoi
Correction to: Severe Dysbiosis and Specific <i>Haemophilus</i> and <i>Neisseria</i> Signatures as Hallmarks of the Oropharyngeal Microbiome in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients
Clinical Infectious Diseases 2022cited by 1position: middledoi
Pathogenese und molekulare Diagnostik der akuten myeloischen Leukämie
Die Onkologie 2022cited by 0position: firstdoi
<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
Blood 2021cited by 162position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Tilmann Bochtler · Zentrum für Qualität in der Pflege30 papers (2013–2025)H. Löffler · Danube Private University16 papers (2012–2023)Jörge E. Cortes · Cecil College14 papers (2018–2020)Albrecht Stenzinger · Chirurgische Universitätsklinik Heidelberg14 papers (2016–2025)Carsten Müller‐Tidow · Heidelberg University14 papers (2012–2023)Alexander E. Perl · Hospital of the University of Pennsylvania14 papers (2018–2020)Marc S. Raab · Memorial Sloan Kettering Cancer Center14 papers (2012–2023)Nigel H. Russell · University of Nottingham13 papers (2018–2020)Mark J. Levis · University of Turin13 papers (2018–2020)Siddhartha Ganguly · Cancer Clinic12 papers (2018–2020)Thomas Hielscher · German Cancer Research Center12 papers (2014–2024)Samer K. Khaled · University of Kansas12 papers (2018–2020)Anthony D. Ho · Mayo Clinic in Arizona11 papers (2012–2017)Hartmut Goldschmidt · Virginia Cooperative Extension10 papers (2012–2023)Volker Endris · Deutschen Konsortium für Translationale Krebsforschung10 papers (2016–2022)Christian Thiede · TiGenix (Spain)9 papers (2012–2022)Gerhard Ehninger · TU Dresden8 papers (2013–2018)Axel Benner · Cancer Research And Biostatistics8 papers (2014–2023)Bianca Kraft · German Cancer Research Center8 papers (2018–2024)Michael Krämer · Mercer University7 papers (2013–2018)